AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06570694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OverThinking
Description: OverThinking is a mobile application ecological momentary intervention for iOS and Android, which has been designed for the reduction of experiential avoidance in rumination. The application primarily consists of psychoeducation content and related exercises intended to be delivered over a four-week period. In order to examine the effectiveness of the application during the course of the intervention and to examine user-experiences of using the application for the purpose of rumination intervention, a number of self-report tools are embedded.
Study NCT06663137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Description: NDV01 is administered intravesically using a catheter.
Study NCT06664437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
Study NCT06664437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
Study NCT06663982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft + L-PRF
Description: After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days.
Study NCT06663982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days.
Study NCT06663696 — intervention group
Intervention type: DEVICE
Intervention: Supraflex Cruz Sirolimus-eluting Coronary Stent System
Description: Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
Study NCT06663007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
Study NCT06663007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
Study NCT06014658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody-Drug Conjugate
Description: MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
Study NCT06075628 — intervention group
Intervention type: OTHER
Intervention: Left Atrial Appendage Occlusion
Description: Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
Study NCT05425810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apply ENABLE sensing pad
Description: The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
Study NCT04890093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-866
Description: PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.
Study NCT04890093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle
Study NCT04890093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle
Study NCT06173063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobility+ Enteral Feeding System
Description: Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
Study NCT05425810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insert small pads at pressure tolerant locations
Description: To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
Study NCT04741984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-201-GBM monocyte vaccine
Description: monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
Study NCT05723029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen Technique
Description: A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
Study NCT05723029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation
Description: Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
Study NCT05437718 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ropivacaine
Description: Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
Study NCT06515496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Scale HLV Clinical Formula Hair Vitamins
Description: For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
Study NCT06515496 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
Study NCT06566625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI (CMR) examination
Description: An MRI examination of the heart (CMR) is presently performed as a follow-up examination in patients where an invasive coronary angiography (ICA) shows no obstructive findings. The intervention in this study is characterized by having the CMR performed before, rather than after, the ICA.~In addition, this study will implement some novel CMR sequences which have not been previously tested in this patient cohort:~* CMR Angiography (imaging the coronary arteries using MRI)~* CMR Fingerprinting (sequences which perform T1 and T2 mapping simultaneously)
Study NCT06656390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK201
Description: Administered intravenously, once every 3 weeks
Study NCT05471973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary Team
Description: Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
Study NCT06658275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Description: During the first routine checkup, therapists will educate caregivers on how to perform the exercises and activities at home. Caregivers will place the childrens less-affected hands in slings and guide them through exercises designed to engage their weaker, paretic hands. The sling will be fastened around the childrens trunks, with the end securely closed.After the initial session, the intervention will be provided by the caregiver at home, with progress monitored by the therapist through Zoom meetings or WhatsApp video calls. Children will engage in play-based activities as part of the CIMT program to improve upper limb functions.These activities will include painting, pin the tail on the donkey for sensory awareness and proprioception, card games, bubble activities, squeezing sponges, building towers with blocks, playing a curtained box game, using tongs, and picking up coins. Exercises will be gradually progressed from easier to more challenging tasks as the child improves.
Study NCT06658275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive Training -HABIT
Description: For the Bimanual Intensive Training group, a strategy similar to HABIT will be used. At the first routine checkup, therapists will educate caregivers on the exercises, which will then be conducted at home. Caregivers will guide children through specially designed bimanual activities without slings, focusing on tasks like reaching, grasping, manipulation, releasing, and bearing weight on the upper limb. Progress will be monitored remotely through Zoom or WhatsApp video calls.Exercises will include catching and throwing a ball to improve reaching, grasp, and release; squeezing a textured ball for sensory awareness and sustained grip; stabilising and reorienting paper while drawing and cutting to enhance forearm supination and wrist extension. Additional tasks like sticker peeling for pincer grip and dough playing for hand manipulation will also be included.Exercises will progress from easy to more difficult as the child improves
Study NCT05760924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
Study NCT05760924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
Study NCT05760924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
Study NCT06607692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib; 177Lu-DOTATATE
Description: 7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
Study NCT05717166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy
Description: Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
Study NCT05717166 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Radiotherapy
Description: Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone therapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Systemic Therapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Systemic Therapy
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Pre-specified based on the standard of care approach for that patient.
Study NCT05717166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily).
Study NCT05717166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR.
Study NCT05717166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency Therapy (RFA)
Description: Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
Study NCT05717166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Radiation
Description: Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation.
Study NCT06277466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs
Description: Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
Study NCT06277466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs
Description: The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.